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Abstract    
 
In the last 30 years several organizations, such as the US Association for the Advancement of 
Medical Instrumentation (AAMI), the British Hypertension Society, the European Society of 
Hypertension (ESH) Working Group on Blood pressure (BP) Monitoring and the International 
Organization for Standardization (ISO) have developed protocols for clinical validation of BP 
measuring devices. However, it is recognized that science, as well as patients, consumers 
and manufacturers would be best served if all BP measuring devices were assessed for 
accuracy according to an agreed single validation protocol that had global acceptance. 
Therefore, an international initiative was taken by AAMI, ESH and ISO experts who agreed to 
develop a universal standard for device validation. This statement presents the key aspects 
of a validation procedure, which were agreed by the AAMI, ESH and ISO representatives as 
the basis for a single universal validation protocol. As soon as the AAMI/ESH/ISO standard is 
fully developed this will be regarded as the single universal standard, and will replace all 
other previous standards/protocols. 
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History of validation protocols 
 
The accurate measurement of blood pressure (BP) is an important prerequisite for the 
reliable diagnosis and efficient management of hypertension and other medical conditions. 
Therefore, the evaluation of the accuracy of automated devices available on the market for 
BP measurement in the medical environment and the community is of paramount 
importance. 
 
Validation of BP measuring devices began in the 1980s with a series of ad hoc validation 
protocols [1]. In 1987 the US Association for the Advancement of Medical Instrumentation 
(AAMI) standard for automated BP monitors included a clinical validation procedure [2]. In 
1990 the British Hypertension Society (BHS) published a protocol dedicated to the validation 
of BP monitors in the clinical setting, which incorporated many of the features of the AAMI 
validation standard, but also had many important differences [3]. The AAMI standard was 
revised in 1992 and 2002 and the BHS protocol in 1993 [4,5]. In 1999 the German 
Hypertension League introduced its own validation protocol [6]. In 2002 the European 
Society of Hypertension (ESH) Working Group on BP Monitoring developed the ESH-
International Protocol (ESH-IP), with the major difference that a smaller sample size was 
required (N=33 compared to N=85 in the AAMI and BHS protocols) [7]. A revised version of 
the ESH-IP with more stringent validation criteria was published in 2010 [8]. In 2009 the 
International Organization for Standardization (ISO) [9] developed another standard, which 
incorporated aspects of EN 1060-4 and the AAMI SP-10 (e.g. sample size and validation 
criteria) and has been adopted by the AAMI Sphygmomanometer Committee [10]. A revised 
version of the American National Standards Institute (ANSI)/AAMI/ISO standard was 
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released in 2013 [11]. Despite whatever differences, all these protocols have major 
similarities and a common objective, namely the standardization of the validation 
procedures to establish minimum standards of accuracy and performance. The history and 
evolving progress of protocols to ensure BP monitors accuracy has recently been reviewed 
[12].   
 
Objective  
 
The authors of the different validation procedures appreciate that science, as well as 
patients, manufacturers and consumers would be best served if all BP measuring devices 
were assessed for accuracy according to an agreed single validation protocol that had global 
acceptance. The aim of this statement is to establish international willingness for a 
universally acceptable protocol, and having done so, to build on past experience to produce 
a single protocol for the validation of BP measuring devices that will replace all previous 
ones. It is not within the scope of the present work to provide a detailed comparison of the 
different validation protocols, which have indeed been the subject of extensive scientific 
discussion and debate in the last two decades [13-22].  
 
AAMI/ESH/ISO collaboration  
 
In acknowledgement of this objective, members of the AAMI, ESH and ISO committees 
agreed to meet and discuss all the aspects of validation that deserve to be reexamined, so as 
to be able to achieve a consensus on an optimal validation standard. 
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The ESH Working Group on BP Monitoring and Cardiovascular Variability, which consists of 
an international group of clinicians with expertise in BP monitoring with members from 
Europe, US, Canada, Japan, China, and Australia, appointed a committee (G Stergiou 
[chairman], R Asmar, N Atkins, JP Ioannidis [medical statistician], R McManus and P Lacy 
[also members of BHS Working Group on BP Monitoring], M Myers, P Palatini, G Parati, A 
Shennan, J Wang, E O’Brien), which met with representatives from AAMI and ISO (ISO/TC 
121/SC 3/JWG 7, Non-invasive sphygmomanometers; B Alpert, S Mieke, D Quinn, S Eckert, G 
Frick, T Graßl, T Ichikawa, A Murray, J Sarkis, T Usuda, C Wu) on 7-8 March 2016 in Berlin, 
Germany.  
 
A list of methodological-statistical and practical-clinical issues for the AAMI/ISO standard and 
the ESH-IP protocol was prepared by the ESH representatives and a medical statistician and 
presented for discussion with the AAMI/ISO representatives during the joint meeting in 
Berlin, Germany. A point-by-point discussion followed, aiming to identify areas of 
agreement, and also disagreement requiring further consideration and research. Another 
AAMI/ESH/ISO meeting took place in April 2017 in Athens, Greece. 
 
This summary report presents the key aspects of a validation procedure, which were agreed 
by the AAMI, ESH and ISO representatives in Athens, as the basis for a single universal 
protocol for the validation of BP monitors to be developed and accepted by all. It is not the 
purpose of this preliminary document to present a detailed description of all the aspects of 
the validation procedure, which will, however, become available as the organizations 
involved develop the procedural detail of the universal protocol. 
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Methodological and clinical issues affecting the validation procedure 
 
Validation study efficacy measure  
 
A tolerable error of 10 mmHg or less (using an individual’s average of three BP readings 
versus a reference BP measurement method) and an estimated probability of that error of at 
least 85% is acceptable as a compromise, taking into account the performance of currently 
available BP monitors. This is compatible with the current ANSI/AAMI/ISO requirements [11] 
and those of the revised ESH-IP allowing for a 10 mmHg error with frequency of 12-18% [8].  
 
This error does not reflect an acceptable level of inaccuracy for BP measurement, but takes 
into account the variability of the validation methodology and also leaves room for devices’ 
accuracy improvement. Setting this level of accuracy is expected to separate devices with 
‘high’ or ‘moderate accuracy’ from those with ‘low accuracy’ (unacceptable). It is stressed 
that ’high accuracy’ does not mean necessarily ‘excellent’. Thus, passing these requirements 
does not equate to ideal accuracy, and some patients may still have inaccurate 
measurements. Clinicians need a higher level of accuracy in BP measurement and encourage 
the industry to continue efforts in technological improvement in order to develop more 
accurate devices.  
 
CONSENSUS 
• A device is considered acceptable if its estimated probability of a tolerable error (≤10 
mmHg) is at least 85%. 
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Validation study sample size 
 
As stated above, a standard is needed which acknowledges potential advances in 
technology, while still allowing for a number of contemporary devices to fulfil the protocol 
requirements. The standard should ensure that ‘high’ and ‘moderate accuracy’ devices will 
pass and ‘low accuracy’ devices will fail. In addition, it should be feasible for the standard to 
be implemented by many research centers.  
  
The optimal sample size for a validation study has been a matter of debate and an important 
point of disagreement between the AAMI/ISO and the ESH-IP, requiring 85 and 33 subjects, 
respectively. A smaller sample size can reduce the cost of validation studies [14]. However, a 
smaller sample size also decreases the study power and accuracy and does not allow 
subgroup evaluation, e.g. for different cuff sizes, age groups, or other special populations 
[14].  
 
A calculation of the power of studies with different sample sizes by Colin Wu, a US NIH 
biostatistician with extensive experience, which was performed specifically for this paper, 
showed that a study with sample size of N=35 is:  
(i) adequate for a ‘high accuracy’ device (defined as mean BP difference between reference 
and test device measurement and its associated standard deviation 0 ± 3-6 [mean±SD] 
mmHg), as it would have <14% chance to fail;  
(ii) adequate for a ‘low accuracy’ device (difference 6-8 ± 5 mmHg, or 0 ± 10-12 mmHg, or 
4-6 ± 8 mmHg), as it would have 94% chance to fail; 
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(iii) inadequate for a ‘moderate accuracy’ device (difference 4±5 mmHg), as it would have 
28% chance to fail, which is unacceptably high.  
On the other hand, with an N=80 study, a ‘moderate accuracy’ device (difference 4±5 
mmHg) has 18% chance to fail, and this is only marginally improved with N=90 (17%).  
 
Given that many of the BP monitors currently available are at the ‘moderate accuracy’ level, 
the N=85 sample size that has been utilized in previous versions of AAMI, ISO and BHS 
standards appears to be reasonable, and also necessary to allow any consideration of cuff-
size stratified or other subgroups and special population evaluations. 
 
CONSENSUS 
• At least 85 subjects are required for an AAMI/ISO/ESH validation study 
 
Cuff-sizes stratified subgroups 
 
This is a necessity as devices often come with two or more cuffs. Although according to the 
formal sample size calculation described above an N=85 study is optimal for each cuff, in 
practice this requirement is unrealistic. It was agreed that a compromise would be to accept 
cuff-size stratified subgroups. These subgroups are not intended for separate analyses (per 
cuff size), but only to ensure an even representation of all cuffs with a minimum number of 
participants. Indeed, these stratified subgroups may hide or smooth the differences 
observed with one cuff. Thus, the mean test-reference BP difference and SD per cuff shall be 
reported. 
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For test devices that have multiple (n) cuffs, each cuff shall be tested on at least 1/(2xn) of 
the subjects, ≥40% of the subjects shall have arm circumference within the upper half of the 
specified range of use of the cuff, ≥40% within the lower half  
 
A proposal was considered for more controlled investigation of cuffs in validation studies, 
which might include the following: (i) a minimum of 22 subjects per cuff, which means that 4 
cuffs could be evaluated in a 88-subject study, and (ii) for test devices that have a single cuff, 
≥40% of the subjects shall have arm circumference within the upper half of the specified 
range of use of the cuff, ≥40% within the lower half, ≥20% within the upper quarter, ≥20 % 
within the lower quarter, ≥10% within the upper octile, and ≥10% within the lower octile. 
 
CONSENSUS 
• There is a minimum number of subjects to be tested per cuff depending on the number of 
the test device cuffs. Cuff subgroups are not intended for separate analyses. 
• Requirements are set for the distribution of the participants’ arm circumference 
according to the specified range of use of the test device. 
 
General population and special populations studies 
 
The AAMI/ESH/ISO protocol should be applicable not only in general population samples 
with normal or high BP, but also in special populations, in which there is theoretical and 
clinical evidence of different accuracy of BP monitors.  
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Special population studies with smaller sample sizes should be performed only after a full 
general population study has been successfully completed. If the device is intended only for 
a special population, then a full 85-subject study is required. Special population study data 
should be analyzed and reported independently of the general population study data. There 
are no specific criteria (pass/fail requirements) defined for special populations, apart from 
pregnancy.  
 
Definition of general population: Consensus was reached that a general population study 
should include only subjects older than 12 years, untreated or treated. The source of 
recruiting both hypertensive and normotensive subjects should be reported. An N=85 adults 
study shall include ≥30% males and ≥30% females, and shall have ≥5% of the reference 
systolic BP readings ≤100 mmHg, ≥5% with ≥160 mmHg, ≥20% with ≥140 mmHg, and ≥5% of 
reference diastolic BP readings ≤60 mmHg, ≥5% with ≥100 mmHg, and ≥20% with ≥85 mmHg 
[11].  
 
Definition of special populations: The following are regarded as special populations: (i) age 
<3 years, (ii) pregnancy including pre-eclampsia, (iii) arm circumference >42 cm, (iv) atrial 
fibrillation. There is no agreed procedure for BP monitor validation in atrial fibrillation. 
Subjects aged 12-21 or >80 years and those with end-stage renal disease were considered as 
possible special groups, but there was uncertainty on the adequacy of existing data 
suggesting altered accuracy of the BP monitors in these groups.  
 
Sample size for special population studies: Although according to the formal sample size 
calculation described above a sample of 85 subjects could be included for each special 
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population, a compromise was agreed to accept a minimum of 35 subjects (45 for 
pregnancy), provided that an independent general population 85-subject study has already 
been completed successfully.  
 
BP distribution criteria for special population studies: Those of general population studies 
cannot be applied but need to be defined for each special population because of their 
different usual BP levels (e.g. children, pregnancy, atrial fibrillation).  
 
Pediatric studies: For devices intended for general population and children, 35 subjects aged 
3-12 years can be included together with 50 subjects aged >12 years, and the BP distribution 
criteria apply to the total 85-subject study. In such studies, further to the formal analysis of 
the total 85-subject sample, the mean systolic and diastolic BP difference (test versus 
reference device) and their SD (Criterion 1) shall also be reported separately for subgroups 
aged 3-12 and >12 years. For devices with a special BP measurement mode for children, 35 
subjects aged 3-12 years shall be included and these are exempt of BP distribution 
requirements. Korotkoff K5 shall be used for reference diastolic BP. If K1 or K5 are not 
audible the child shall be excluded.  
 
Pregnancy and pre-eclampsia: Include 45 women in 2nd and 3rd trimesters of pregnancy, of 
whom 15 with pre-eclampsia, defined as elevated systolic BP ≥140 mmHg and/or diastolic 
≥90 mmHg with proteinuria, 15 with gestational hypertension (new onset in pregnancy with 
systolic BP ≥140 mmHg and/or diastolic ≥90 mmHg without proteinuria), and 15 
normotensives. Korotkoff K5 shall be used for reference diastolic BP. Age criteria and BP 
distribution criteria will not be applied. The pass/fail criterion 1 of the ANSI/AAMI/ISO 
13 
 
 
81060-2:2013 (mean difference of test versus reference BP measurements ≤5 mmHg with SD 
≤8 mmHg for systolic and diastolic BP) [11] will be applied in the 45 women sample. Data 
from pre-eclamptics (mean difference and SD) shall be reported separately to allow 
comparison across studies.  
 
CONSENSUS 
• A general population study should include only subjects older than 12 years. 
• Special populations include at least: (i) age <3 years, (ii) pregnancy including pre-
eclampsia, (iii arm circumference >42 cm), (iv) atrial fibrillation. Other special populations 
may be added as special groups. 
• Special population studies to include ≥35 subjects, provided that a general population 
study has been completed successfully. For special populations BP distribution criteria to 
differ from those of general population studies. Data to be analyzed independently of 
general population study data. 
• Studies in pregnancy to include 45 women of whom 15 with pre-eclampsia, 15 with 
gestational hypertension, 15 normotensive. Korotkoff K5 shall be used for reference 
diastolic BP. 
• For devices intended for adults and children, 35 subjects aged 3-12 years can be included 
and analyzed together with 50 subjects aged >12 years. Mean BP difference and SD shall 
also be reported separately for age 3-12 and >12 years groups. Korotkoff K5 shall be used 
for reference diastolic BP. 
 
Method for BP data collection 
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The same arm sequential method (table 1) is by far the most well-studied and supported by 
all protocols [1-11]. Thus, this is the preferred method for BP data collection. As the test 
device cuff may not fulfill the requirements for reference auscultatory BP measurement and 
some devices have fast deflation rate or measure BP during inflation, it was agreed that the 
same arm simultaneous method is no longer included as a possibility. The opposite arm 
simultaneous method will be retained as presented in the ANSI/AAMI/ISO protocol [11]. 
 
CONSENSUS 
• The same arm sequential BP measurement is the preferred method for validation. 
• The same arm simultaneous method has been eliminated. 
 
Reference BP measurement and validation procedure 
 
The auscultatory standard is retained for reference BP measurement with measurements 
taken simultaneously by two trained observers blinded to each-other’s readings and to the 
measurements taken with the test device (Y-tube connected double stethoscope; observers 
qualified for their agreement according to the BHS protocol criteria within 12 months before 
the validation [3]; baseline and repeat audiogram every 3 years). Korotkoff K1 shall be used 
for reference systolic BP and K5 for diastolic BP in all subjects, including adults, adolescents, 
children aged ≥3 years, and pregnancy. If K1 or K5 is not audible the subject shall be 
excluded. A third observer (supervisor) is necessary to supervise the validation procedure, 
the adequacy of reference and test device BP measurements, the agreement between the 
two observers who should be unaware of the magnitude or direction of their disagreement, 
and any other issue during the validation procedure.  
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The validation procedure starts with the subject seated comfortably and relaxed for at least 
5 min, her/his back and arm supported with the middle of the upper arm at heart level, legs 
uncrossed and feet flat on the floor. Talking and any other interference needs to be avoided 
throughout the entire validation procedure. The sequential method (Table 1) requires a 
reference BP measurement (R0) taken by the two observers, followed by a test device 
measurement (T0) to confirm the device function. Then 4 reference BP measurements 
follow, alternated by 3 test device measurements (R1-T1-R2-T2-R3-T3-R4). Measurements will 
be performed with at least 60-second intervals.  
 
The supervisor will review each pair of test/reference BP measurements. If one of them (test 
or reference BP) has to be excluded (due to test device failure or observers’ disagreement >4 
mmHg in systolic or diastolic BP), then another pair of BP readings (test and reference) is 
taken. A maximum of 8 pairs is allowed (4 additional pairs). Observers’ BP comparison during 
the validation study shall be reported (mean difference, SD and range), together with the 
number of repeated measurements. Subjects with systolic BP difference >12 mmHg and/or 
diastolic >8 mmHg in any 2 of the 4 reference (average of two observers) BP measurements 
(R1 to R4) shall be excluded.  
 
Because of concern with mercury toxicity, in many countries mercury devices are not 
available, or the maintenance of mercury sphygmomanometers is very difficult. Therefore, 
reference BP measurements can be obtained using mercury sphygmomanometers, or non-
mercury manometers (aneroid or other) that fulfill the ISO 81060-1 requirements for 
accuracy (maximum permissible error shall be ±1 mmHg) [9]. The accuracy of non-mercury 
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devices shall be evaluated against a mercury sphygmomanometer or a calibrated and 
certified pressure device at the beginning of each validation study. National metrology 
institutes and other institutions might provide such calibration services.  
 
The cuffs used for reference auscultatory BP measurement shall have an inflatable bladder 
length that covers 75-100% of the arm circumference of each subject and width that covers 
37-50% of the arm circumference. The test device cuffs shall not be used for reference BP 
determination. Detailed description of cuffs used for reference BP measurement shall be 
reported in each study (manufacturer, construction, bladder dimensions). An example of 
cuff use (inflatable bladder dimensions) for reference auscultatory BP measurement in a 
general population validation study including children is shown in Table 2. 
 
CONSENSUS 
• Reference BP measurement to be performed with mercury sphygmomanometers or 
accurate non-mercury devices. The accuracy of non-mercury devices shall be evaluated at 
the beginning of each study. 
• Detailed description of cuffs used for reference BP measurement shall be provided.  
• The test device cuffs shall not be used for reference BP determination. 
 
Validation criteria and reporting  
 
Each of the reference BP measurements (R0-R4) is the average of the simultaneous readings 
of the two observers. Each of the test device measurements is compared against the average 
of the previous and next reference BP reading (e.g. T1 versus the average of R1-R2, T2 versus 
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average of R2-R3, T3 versus average of R3-R4). Differences are calculated by subtracting the 
reference BP measurement from the test device measurement. The mean BP difference (test 
versus reference device) and its SD, i.e., Criteria 1 and 2 of the ANSI/AAMI/ISO 81060-2:2013 
[11] will be applied for the AAMI/ESH/ISO validation data evaluation. The same criteria will 
be used for systolic and diastolic BP measurements. In studies including children, further to 
the total 85-subject analysis, the mean systolic and diastolic BP difference and their SD 
(Criterion 1) shall also be reported separately for subgroups aged 3-12 years and >12 years.  
 
The number of absolute BP differences (test BP minus average of previous and next 
reference BP readings) within 5, 10 and 15 mmHg used by the ESH-IP [8] shall also be 
reported. This categorization is important so that the validation data can be understood by a 
variety of potential users, i.e. clinicians, public, industry, etc. Standardized Bland-Altman 
scatterplots as shown in Figure 1 [8] will be presented in the AAMI/ESH/ISO validation study 
report. 
 
CONSENSUS 
• The mean BP difference (test versus reference) and its SD, Criteria 1 and 2 of the 
ANSI/AAMI/ISO 81060-2 [11], to be applied for systolic and diastolic BP.  
• The number of absolute BP differences within 5, 10 and 15 mmHg and standardized 
Bland-Altman scatterplots will be presented. 
 
Validation of other BP monitors 
 
18 
 
 
• Separate validation protocols need to be developed for specific functions of certain BP 
monitors, including continuous, cuffless and central BP monitors. Task groups have been 
established to explore the methodology of such protocols. 
• Devices that have more than one BP measurement mode (e.g. auscultatory and 
oscillometric) require separate validation of each mode in an 85-subject study. Devices 
that have peripheral (brachial) and other BP measurement mode (e.g. central BP) should 
first be assessed for peripheral BP measurement accuracy using the main 85-subject 
study. 
 
CONSENSUS 
• Separate validation protocols will be developed for continuous, cuffless and central BP 
monitors. 
 
Quality and reliability of validation study reports 
 
Violations of the validation protocols and incomplete reporting (missing and unclear data) 
are particularly common and are likely to be missed by the peer-review process of scientific 
journals [23-26]. Tools and forms (printed and electronic) for reporting complete data from 
validation studies similar to those in the revised ESH-IP [8] should be developed in order to 
prevent protocol violations and incomplete reporting. 
 
Measures to ensure transparency in selecting data for inclusion into analysis should be 
applied i.e. providing reasons for excluding data and stipulating inclusion in chronological 
order to fill BP ranges (e.g. electronic online patient report forms). This provides safeguards 
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against potential exclusion of inaccurate data when actual sample size exceeds specified 
sample size and is necessary to fill BP ranges. 
 
CONSENSUS 
• Tools need to be developed to prevent protocol violations and incomplete reporting and 
to secure appropriate and transparent patient and data selection.  
• Detailed forms should be developed to fill in all the data from validation studies that need 
to be reported. 
 
Further procedures 
 
The objective of this initiative is to satisfy the existing need for a single standard for BP 
monitor validation to be internationally accepted and used. The AAMI, ESH and ISO experts 
agreed to develop a universal standard for device validation, as described in this statement. 
This preliminary document does not present a detailed description of all the aspects of the 
validation procedure, which will become available as the organizations involved develop the 
universal protocol in more detail. As soon as the AAMI/ESH/ISO standard is fully developed 
this will be regarded as the single universal standard, and will replace all other previous 
standards/protocols. 
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Figure 1. 
 
Legend 
Standardized Bland-Altman scatterplots as shown below [8] will be presented in the 
AAMI/ESH/ISO validation study report. 
 
 
 
Footnote 
The x-axis represents BPs in the systolic range 80-190 mmHg and diastolic 30-140 mmHg. The 
y-axes represent errors from -30 to +30 mmHg. Horizontal reference lines are drawn at 5 
mmHg intervals from +15 to -15 mmHg. The mean of each device BP and its corresponding 
observer BP is plotted against their difference with a point. Differences >30 mmHg are plotted 
at 30 mmHg. Differences <-30 mmHg are plotted at -30 mmHg. Vertical lines represent BP 
distribution boundaries. The same y-axis scale should be used for systolic and diastolic BP plots 
[8].  
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Table 1.  
Procedure for reference and test device BP measurements in same arm sequential validation 
method.  
 
INITIAL BP MEASUREMENTS*  
1.  Take reference BP measurement by the 2 observers  R0 
2.  Take test device BP measurement  T0 
VALIDATION BP MEASUREMENTS FOR ACCURACY EVALUATION  
3.  Take 1st reference BP measurement by the 2 observers  R1 
4.  Take 1st test device BP measurement  T1 
5.  Take 2nd reference BP measurement by the 2 observers  R2 
6.  Take 2nd test device BP measurement  T2 
7.  Take 3rd reference BP measurement by the 2 observers  R3 
8.  Take 3rd test device BP measurement  T3 
9.  Take 4th reference BP measurement by the 2 observers  R4 
 
* Measurement R0 shall not be used in the evaluation of reference BP distribution and 
variability criteria. Measurements R0 and T0 shall not be used in the evaluation of the test 
device accuracy. 
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Table 2.  
Example of cuff use (inflatable bladder dimensions) for reference auscultatory BP 
measurement in a general population validation study including children. 
 
 Participant’s mid-arm circumference (cm) 
 12-15 15-18 18-23 23-28 28-35 33-42 
Bladder length 
(cm) 
12 15 18 23 28 33 
Bladder width 
(cm) 
6 7 9 12 14 16 
 
